Literature DB >> 36279081

Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light.

Jie Zhang1, Kanghui Wu1, Cuicui Shi2, Guangming Li3.   

Abstract

OPINION STATEMENT: Immunotherapy is revolutionizing tumor treatment by activating the immune response to tumors. Among them, immunotherapy represented by immune checkpoint inhibitors is considered to be a milestone in tumor treatment. It has revolutionized the management of advanced malignant tumors by activating T cells, promoting cytotoxic signaling pathways, and killing tumor cells, effectively improving the overall survival of patients. However, resistance to immunotherapy and immune-related adverse events remain challenges for immunotherapy. It has been demonstrated in previous studies that modulating intestinal microbiota can enhance immunotherapy response and reduce complications. Currently, the more mature method for microbiota regulation is fecal microbiota transplantation, which involves transfering a donor's microbiome to the recipient in the form of capsules or fecal microbiota suspension to restore the richness of the recipient's intestinal microbiota. In terms of cancer immunotherapy, fecal microbiota transplantation in patients who fail to respond to immune checkpoint inhibitors is expected to produce better prognosis for patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer; Fecal microbiota transplantation; Immune checkpoint inhibitors; Immunotherapy

Year:  2022        PMID: 36279081     DOI: 10.1007/s11864-022-01027-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  51 in total

1.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

Review 2.  A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.

Authors:  Neeraj Chhabra; Joseph Kennedy
Journal:  J Med Toxicol       Date:  2021-04-07

Review 3.  The interplay between host immune cells and gut microbiota in chronic inflammatory diseases.

Authors:  Donghyun Kim; Melody Y Zeng; Gabriel Núñez
Journal:  Exp Mol Med       Date:  2017-05-26       Impact factor: 8.718

4.  Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine.

Authors:  Nicolas Benech; Harry Sokol
Journal:  Genome Med       Date:  2020-06-30       Impact factor: 11.117

Review 5.  Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.

Authors:  Jii Bum Lee; Hye Ryun Kim; Sang-Jun Ha
Journal:  Immune Netw       Date:  2022-02-14       Impact factor: 5.851

6.  16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome.

Authors:  Daniel E Almonacid; Laurens Kraal; Francisco J Ossandon; Yelena V Budovskaya; Juan Pablo Cardenas; Elisabeth M Bik; Audrey D Goddard; Jessica Richman; Zachary S Apte
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.752

Review 7.  Gut microbiome modulates efficacy of immune checkpoint inhibitors.

Authors:  Ming Yi; Shengnan Yu; Shuang Qin; Qian Liu; Hanxiao Xu; Weiheng Zhao; Qian Chu; Kongming Wu
Journal:  J Hematol Oncol       Date:  2018-03-27       Impact factor: 17.388

Review 8.  Resistance to Checkpoint Inhibition in Cancer Immunotherapy.

Authors:  Luisa Barrueto; Francheska Caminero; Lindsay Cash; Courtney Makris; Purushottam Lamichhane; Rahul R Deshmukh
Journal:  Transl Oncol       Date:  2020-02-27       Impact factor: 4.243

Review 9.  The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment.

Authors:  Sang Hoon Kim; Yun Jeong Lim
Journal:  Intest Res       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.